Granulocytic sarcoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

WikiDoc Resources for Granulocytic sarcoma
Articles
Most recent articles on Granulocytic sarcoma Most cited articles on Granulocytic sarcoma Review articles on Granulocytic sarcoma Articles on Granulocytic sarcoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Granulocytic sarcoma Images of Granulocytic sarcoma Photos of Granulocytic sarcoma Podcasts & MP3s on Granulocytic sarcoma Videos on Granulocytic sarcoma
Evidence Based Medicine
Cochrane Collaboration on Granulocytic sarcoma Bandolier on Granulocytic sarcoma TRIP on Granulocytic sarcoma
Clinical Trials
Ongoing Trials on Granulocytic sarcoma at Clinical Trials.gov Trial results on Granulocytic sarcoma Clinical Trials on Granulocytic sarcoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Granulocytic sarcoma NICE Guidance on Granulocytic sarcoma NHS PRODIGY Guidance FDA on Granulocytic sarcoma CDC on Granulocytic sarcoma
Books
Books on Granulocytic sarcoma
News
Granulocytic sarcoma in the news Be alerted to news on Granulocytic sarcoma News trends on Granulocytic sarcoma
Commentary
Blogs on Granulocytic sarcoma
Definitions
Definitions of Granulocytic sarcoma
Patient Resources / Community
Patient resources on Granulocytic sarcoma Discussion groups on Granulocytic sarcoma Patient Handouts on Granulocytic sarcoma Directions to Hospitals Treating Granulocytic sarcoma Risk calculators and risk factors for Granulocytic sarcoma
Healthcare Provider Resources
Symptoms of Granulocytic sarcoma Causes & Risk Factors for Granulocytic sarcoma Diagnostic studies for Granulocytic sarcoma Treatment of Granulocytic sarcoma
Continuing Medical Education (CME)
CME Programs on Granulocytic sarcoma
International
Granulocytic sarcoma en Espanol Granulocytic sarcoma en Francais
Business
Granulocytic sarcoma in the Marketplace Patents on Granulocytic sarcoma
Experimental / Informatics
List of terms related to Granulocytic sarcoma

Education:

2018: Graduated in Medicine from Shahid Beheshti University of Medical Sciences

Thesis: MRI features of pituitary adenoma predicting its resectability

2007-2011: Farzanegan High School (NODET: National Organization for Development of Exceptional Talents)

Presentations:

Poster presentation at First Sharif Symposium of Neurosciences, Taallohi Sh, Jabbari P, Alavi M, Mohammadsadeghi H. Time Perception in Bipolar mood disorder vs Borderline personality disorder

Professional Membership and Activities:

International Federation of Medical Students’ Associations (IFMSA): local head of SCORA (Sexual and Reproductive Health Including HIV/AIDS) at Shahid Beheshti Medical School (2015-2016)

GID (gender identity disorder) Association (2015-2016)

Teaching at Peer Educator Training workshops (IFMSA)

Languages:

Persian (mother tongue)

English: fluent

French: fluent

Historical Perspective

• Granulocytic sarcoma (GS, also known as chloroma) was first discovered by Allen Burns, a British physician, in 1811 .
• The term chloroma was first used by King to address the greenish appearance of the tumor due to myeloperoxidase.
• The association of the GS with acute myeloid leukemia was first recognized bt Dock in 1902 .
• The term granulocytic sarcoma was suggested by Rappaport in 1967 to grant generalisability to it .
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].